You are currently browsing the archives for 31 May 2016.
Displaying 1 entry.

The vaccine will be initially for use by specialists practicing veterinary oncology.

A study by Dr. Philip Bergman of the AMC, seeking novel treatments for canine melanoma resulted in a clinical trial of the Memorial Sloan – Kettering melanoma vaccine at The Animal Medical Center. Dogsallel trials at AMC and MSKCC refined the dosage and protocol to the current therapeutic regimen for dogs. Both humans and dogs develop this cancer, the exact same way the disease spontaneously through an interaction of genes with the environment, explained Jedd D. Wolchok, an oncologist on the Clinical Immunology Service at Memorial Sloan – Kettering. Through the implementation of tests in humans and animals that live in the same environment there can be a there can be a synergy that we hope will result in improved cancer treatment for all.

The unit was developed in collaboration with Bioject, a Portland-based research pharmaceutical company develops. – ‘We are all very proud of what we have achieved,’said Tim Leard, Director of Biologics Research and Development at Merial. ‘We of partners of partners, all committed innovations and discoveries. This product will improve the health and welfare of dogs, and we are very pleased to continue this work, excited using technology and the development of more treatments. ‘.. Merial obtained licensing rights from MSKCC and AMC, and with their access to and experience with DNA vaccine technology from Vical Incorporated licensed, completed the industrialization and regulatory requirements for conditional approval.